Log in

NASDAQ:CLBS - Caladrius Biosciences Stock Price, Forecast & News

$2.84
-0.11 (-3.73 %)
(As of 02/26/2020 02:43 AM ET)
Today's Range
$2.83
Now: $2.84
$3.05
50-Day Range
$2.73
MA: $3.01
$3.47
52-Week Range
$2.00
Now: $2.84
$4.36
Volume13,494 shs
Average Volume25,859 shs
Market Capitalization$29.54 million
P/E RatioN/A
Dividend YieldN/A
Beta1.58
Caladrius Biosciences, Inc is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.

Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLBS
CUSIPN/A
Phone908-842-0100

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.81 per share

Profitability

Net Income$-16,170,000.00

Miscellaneous

EmployeesN/A
Market Cap$29.54 million
Next Earnings Date3/12/2020 (Estimated)
OptionableOptionable

Receive CLBS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLBS and its competitors with MarketBeat's FREE daily newsletter.


Caladrius Biosciences (NASDAQ:CLBS) Frequently Asked Questions

What is Caladrius Biosciences' stock symbol?

Caladrius Biosciences trades on the NASDAQ under the ticker symbol "CLBS."

How were Caladrius Biosciences' earnings last quarter?

Caladrius Biosciences Inc (NASDAQ:CLBS) posted its earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.04. View Caladrius Biosciences' Earnings History.

When is Caladrius Biosciences' next earnings date?

Caladrius Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Caladrius Biosciences.

What price target have analysts set for CLBS?

3 analysts have issued 12-month price objectives for Caladrius Biosciences' stock. Their forecasts range from $6.00 to $6.75. On average, they anticipate Caladrius Biosciences' stock price to reach $6.38 in the next year. This suggests a possible upside of 124.5% from the stock's current price. View Analyst Price Targets for Caladrius Biosciences.

What is the consensus analysts' recommendation for Caladrius Biosciences?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Caladrius Biosciences in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Caladrius Biosciences.

Has Caladrius Biosciences been receiving favorable news coverage?

Headlines about CLBS stock have been trending neutral recently, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Caladrius Biosciences earned a news sentiment score of 0.2 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Caladrius Biosciences.

Who are some of Caladrius Biosciences' key competitors?

What other stocks do shareholders of Caladrius Biosciences own?

Who are Caladrius Biosciences' key executives?

Caladrius Biosciences' management team includes the folowing people:
  • David J. Mazzo, President, Chief Executive Officer & Director
  • Joseph Talamo, CFO, Principal Accounting Officer & Senior VP
  • Douglas W. Losordo, Chief Medical Officer & Executive Vice President
  • Greg Berkin, Vice President-Information Technology
  • John D. Menditto, VP-Investor Relations & Corporate Communications

Who are Caladrius Biosciences' major shareholders?

Caladrius Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (3.96%). View Institutional Ownership Trends for Caladrius Biosciences.

Which institutional investors are buying Caladrius Biosciences stock?

CLBS stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Caladrius Biosciences.

How do I buy shares of Caladrius Biosciences?

Shares of CLBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Caladrius Biosciences' stock price today?

One share of CLBS stock can currently be purchased for approximately $2.84.

How big of a company is Caladrius Biosciences?

Caladrius Biosciences has a market capitalization of $29.54 million. The biotechnology company earns $-16,170,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis. View Additional Information About Caladrius Biosciences.

What is Caladrius Biosciences' official website?

The official website for Caladrius Biosciences is http://www.caladrius.com/.

How can I contact Caladrius Biosciences?

Caladrius Biosciences' mailing address is 110 ALLEN ROAD 2ND FLOOR, BASKING RIDGE NJ, 07920. The biotechnology company can be reached via phone at 908-842-0100 or via email at [email protected]


MarketBeat Community Rating for Caladrius Biosciences (NASDAQ CLBS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  302 (Vote Outperform)
Underperform Votes:  262 (Vote Underperform)
Total Votes:  564
MarketBeat's community ratings are surveys of what our community members think about Caladrius Biosciences and other stocks. Vote "Outperform" if you believe CLBS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLBS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel